MetaCap

Cocrystal Pharma (COCP) vs China Pharma (CPHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cocrystal Pharma (COCP) has outperformed China Pharma (CPHI) over the past year, gaining 5.6% versus a loss of 72.6%. Over five years, COCP leads with a -91.8% price change compared with -99.8% for CPHI. China Pharma is the larger company by market cap ($18.9 million vs $18.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COCP+5.56%CPHI-72.60%
+430%+167%-97%
Nov 21, 20251 yearNov 20, 2026
COCP-90.35%CPHI-99.85%
+24%-41%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COCP versus CPHI key metrics
MetricCOCPCPHI
Share price$0.95$0.4384
Market cap$18.30M$18.86M
1-day change-2.05%-13.00%
YTD return-3.06%-63.77%
1-year return+5.56%-72.60%
5-year return-91.84%-99.84%
EPS (TTM)$-0.76$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.14M
Revenue growth (YoY)—-8.49%
Net income (latest FY)$-8.83M$-3.19M
Gross margin—-3.18%
Operating margin—-78.16%
Net margin—-76.91%
52-week high$2.03$19.19
52-week low$0.76$0.38
Distance from 52-week high-53.20%-97.72%
Analyst consensusnone—
Avg. price target upside+847.37%—
Average volume40.65K1.60M
Shares outstanding19.26M43.02M
Employees10215
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • COCP has outperformed CPHI by 78.2 percentage points over the past year.

About Cocrystal Pharma

COCP stock →

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

COCP vs CPHI FAQ

Which is bigger, Cocrystal Pharma or China Pharma?

China Pharma (CPHI) is larger, with a market capitalization of $18.86M compared with $18.30M for Cocrystal Pharma (COCP).

Which stock has performed better over the past year, COCP or CPHI?

COCP returned +5.56% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.

Are Cocrystal Pharma and China Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons